- Do you, or did you, own shares of Avalanche Biotechnologies, Inc. (NASDAQ GM: AAVL)?
- Did you purchase your shares pursuant and/or traceable to the initial public offering on or about July 31, 2014, or between July 31, 2014 and June 15, 2015, inclusive?
- Did you lose money in your investment in Avalanche Biotechnologies, Inc.?
Please contact Rigrodsky & Long, P.A. (“R & L”) to schedule a free consultation. You may call us or fill out our contact form so that we can call at your convenience. Your consultation will not create any obligation to use our services at any time.
R & L is investigating claims brought in a securities fraud class action complaint against Avalanche Biotechnologies, Inc. ("Avalanche") concerning whether Avalanche and certain of the Company’s directors and/or officers made materially false and misleading statements and failed to disclose materially adverse facts between July 31, 2014 and June 15, 2015, inclusive, including those investors who acquired Avalanche shares pursuant to or traceable to its initial public offering commenced on July 31, 2014 (the “Class Period”), concerning the Company’s business, operations and prospects. These misrepresentations and omissions artificially inflated the price of the Company's stock throughout the Class Period.